In the past year, this Zacks Rank #3 (Hold) stock has rallied 38.1% against the industry’s 7.4% fall and the S&P 500 composite’s 9.1% rise. The renowned medical device company has a market ...

The U.S. government’s $1.6 billion in CHIPS Act grant and TXN’s entry into the edge AI space are added upsides for this Zacks Rank #3 (Hold) stock. Considering all these factors, we recommend ...